B-cell
Showing 26 - 50 of >10,000
DLBCL Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Jul 11, 2023
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)
Not yet recruiting
- Non Hodgkin Lymphoma
- +5 more
- Pirtobrutinib
- LV20.19 CAR T cells
- (no location specified)
Aug 4, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)
Not yet recruiting
- Relapsed/Refractory B-Cell Lymphoma
- FT522
- +4 more
- (no location specified)
Jul 10, 2023
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- infusion of JY231 injection
-
Guangzhou, Guangdong, ChinaGuangdong Second Provincial General Hospital
Sep 17, 2023
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
Recruiting
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
-
Milan, ItalyOspedale San Raffaele
Aug 29, 2023
Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- +5 more
- P-CD19CD20-ALLO1
- Rimiducid
-
La Jolla, California
- +7 more
Aug 25, 2023
DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- High-grade B-cell Lymphoma
- Loncastuximab Tesirine
- (no location specified)
Dec 13, 2022
Non-hodgkin Lymphoma Trial (HY004)
Not yet recruiting
- Non-hodgkin Lymphoma
- HY004
- (no location specified)
Aug 21, 2023
Relmacabtagene Autoleucel in Patients With LBCL
Recruiting
- Large B-cell Lymphoma
- Relmacabtagene Autoleucel
-
Shanghai, Shanghai, ChinaRuijin Hospital Affiliated to Shanghai Jiao Tong University Scho
Nov 15, 2023
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
- (no location specified)
Mar 9, 2023
B-cell Lymphoma Trial in Stockholm, Uppsala (CAR20(NAP)-T, Cyclophosphamide, Fludarabine)
Not yet recruiting
- B-cell Lymphoma
- CAR20(NAP)-T
- +2 more
-
Stockholm, Sweden
- +1 more
Aug 15, 2023
Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Relapsed/Refractory Large B-cell Lymphoma
- KITE-197
- +2 more
- (no location specified)
Oct 6, 2023
Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)
Not yet recruiting
- Relapsed or Refractory B-cell Lymphoma
- Relmacabtagene Autoleucel Injection
- (no location specified)
Apr 13, 2023
Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:
Completed
- Diffuse Large B-cell Lymphoma
-
East Hanover, New JerseyNovartis
Jun 16, 2023
Hematopoietic Stem Cell Transplantation, Hematologic Malignancy Trial (CliniMACS®)
Not yet recruiting
- Hematopoietic Stem Cell Transplantation
- Hematologic Malignancy
- CliniMACS®
- (no location specified)
Oct 17, 2023
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022
Not yet recruiting
- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Fludarabine (30 mg/m^2)
- +2 more
- (no location specified)
Jul 25, 2023
Frontline of ASCT in High-risk DLBCL
Recruiting
- Diffuse Large B Cell Lymphoma
-
Beijing, Beijing, ChinaPeking University People's Hospital
Apr 26, 2023
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +4 more
-
Birmingham, United Kingdom
- +5 more
Sep 18, 2023
Cardiovascular Events Among Adults Relapsed or Refractory
Recruiting
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
- +9 more
- Electronic Health Record Review
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)
Recruiting
- B Cell Lymphoma
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 3, 2023
Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)
Available
- Large B-cell Lymphoma
- +4 more
- Epcoritamab
- (no location specified)
Feb 16, 2023
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)
Recruiting
- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
- dualCAR-NK19/70 cell
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023